Fludarabine + Cyclophosphamide + Thymoglobulin
Phase 1Terminated 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Scleroderma
Conditions
Scleroderma, Systemic Sclerosis
Trial Timeline
Jul 1, 2002 → Mar 1, 2007
NCT ID
NCT00040651About Fludarabine + Cyclophosphamide + Thymoglobulin
Fludarabine + Cyclophosphamide + Thymoglobulin is a phase 1 stage product being developed by Amgen for Scleroderma. The current trial status is terminated. This product is registered under clinical trial identifier NCT00040651. Target conditions include Scleroderma, Systemic Sclerosis.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00040651 | Phase 1 | Terminated |
Competing Products
15 competing products in Scleroderma
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| IVA337 + Placebo | Inventiva | Phase 2 | 47 |
| Cuprimine (penicillamine) | Merck | Pre-clinical | 23 |
| rapcabtagene autoleucel + rituximab | Novartis | Phase 2 | 52 |
| STI571 | Novartis | Phase 2 | 52 |
| Imatinib mesylate | Novartis | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2 | 52 |
| Mycophenolate mofetil | Roche | Pre-clinical | 23 |
| Mycophenolate mofetil + Cyclophosphamide + Placebo | Roche | Phase 2 | 52 |
| BMS-986020 | Bristol Myers Squibb | Phase 2 | 51 |
| dasatinib | Bristol Myers Squibb | Phase 1/2 | 40 |
| Abatacept + Placebo | Bristol Myers Squibb | Phase 1/2 | 40 |
| AVID200 | Bristol Myers Squibb | Phase 1 | 32 |
| Rilonacept | Regeneron Pharmaceuticals | Phase 1/2 | 40 |
| Riociguat + Placebo | Bayer | Phase 2 | 49 |
| Riociguat (Adempas, BAY63-2521) + Placebo | Bayer | Phase 2 | 49 |